The Impact of 5-HT3RA Use on Cost and Utilization in Patients with Chemotherapy-Induced Nausea and Vomiting: Systematic Review of the Literature.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Individual studies have assessed the impact of standard prophylactic therapy with 5-hydroxytryptamine receptor antagonists (5-HT3RAs) for chemotherapy-induced nausea and vomiting (CINV) on cost and utilization, but no synthesis of the findings exists.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Am Health Drug Benefits

Title: American health & drug benefits

ISSN: 1942-2962

ISSN (Print): 1942-2962

Publication date (Electronic): May 2014

Volume: 7

Issue: 3

Affiliations

[1 ] President, Partnership for Health Analytic Research, LLC, Beverly Hills, CA.

[2 ] Director, Health Economics and Outcomes Research, Eisai Inc, Woodcliff Lake, NJ.

[3 ] Senior Director, Health Economics and Outcomes Research (HEOR) and Reimbursement Services, Eisai Inc, Woodcliff Lake, NJ.

[4 ] Associate Medical Director, Partnership for Health Analytic Research, LLC, Beverly Hills, CA.

[5 ] Associate Director, Outcomes Research, Partnership for Health Analytic Research, LLC, Beverly Hills, CA.

Article

PMC ID: 4070626

PubMed ID: 24991400

SO-VID: 067c916b-5bc0-4729-803b-1a5b71235750

History

Data availability:

Comments

Comment on this article

Cited by 3

See all cited by